Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Monday, April 6, 2020 · 513,899,971 Articles · 3+ Million Readers

Global Carrier Screening Market Forecast 2019-2029: Capitalizing on the Potential Presented by the Emerging Markets of Asia

/EIN News/ -- Dublin, Aug. 30, 2019 (GLOBE NEWSWIRE) -- The "Global Carrier Screening Market: Focus on Product Type, Technology Type, 18 Countries Data, Autosomal Recessive Disorders, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.

With a substantial increase in the demand for the carrier screening test and diagnostics tests based on sequencing, the carrier screening market is expected to witness impressive growth and promises to be a lucrative field for investment.

Carrier screening is a medical investigation to detect whether a carrier gene for a recessive disorder is present in a couple or a person, who does not know about the increased risk of being a carrier based on their partner and family history. Carrier screening can be considered at different life stages, for instance, by individuals or couples before pregnancy or even before the relationships commence.

Carrier screening is distinguished from newborn screening, which aims at detecting newborn with severe treatable diseases for early treatment and prevention. In communities with high burden of severe diseases, population prevention is said to be the appropriate aim of carrier screening, and in those cases reduced birth rates of affected children may be regarded as measure of success.

Introduction of new genetic technologies has made it possible to detect a much wider range of sequence variants, and simultaneously screen for different diseases at a faster turnaround time without significantly increasing the cost.

In North America, Australia, and Europe, the number of commercial laboratories is increasing and are also offering panels for carrier screening for over 100 diseases. A distinguished feature of carrier screening with diagnostic testing is that the test is usually offered to people with any symptom or sign of a specific health problem and increased risk.

Key Questions Answered

  • How the carrier screening market is expected to have an impact on the healthcare industry?
  • What was the total revenue generated by the global carrier screening market for autonomous in 2018 and how is it expected to grow during 2019 - 2029?
  • How are the transformational trends and major driving forces in this technology are expected to yield new business opportunities?
  • Which sub-segment of the global carrier screening market by disease, such as down syndrome, sickle cell anemia, cystic fibrosis, hemophilia, spinal muscular atrophy, fragile x syndrome, thalassemia, other autosomal recessive genetic disorders, during the forecast period, 2019-2029?
  • Which region, such as North America, Europe, Asia-Pacific, Latin-America is expected to grow the fastest in the global carrier screening market?
  • What are the key developmental strategies which are being implemented by the key players to stand out in this market?

Topics Covered

Executive Summary

1 Market Overview

2 Market Dynamics
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Availability of Advanced Screening Technologies
2.2.2 Shift of Reimbursement Policies Toward More Genetics Coverage
2.2.3 Increasing Prevalence of Genetic and Congenital disorders
2.2.4 Increasing Consumer Demand
2.3 Market Restraints
2.3.1 Limited Clinical Experience
2.3.2 General Public May Lack Interest in Expanded Carrier Screening
2.3.3 Technical Challenges of the Knowledge Base and Newer Sequencing Platforms
2.4 Market Opportunities
2.4.1 Genetic Counselling Needs to be Adapted for Expanded Carrier Screening Services
2.4.2 Availability of Direct-to-Consumer Tests
2.4.3 Capitalizing on the Potential Presented by the Emerging Markets of Asia

3 Competitive Landscape
3.1 Key Strategies and Developments
3.1.1 Collaborations, Partnerships, Joint Ventures, and Agreements
3.1.2 Business Expansion and Funding
3.1.3 Product Launch and Enhancements
3.1.4 Mergers and Acquisitions
3.2 Market Share Analysis

4 Industry Insights
4.1 Appropriate Use Criteria
4.1.1 Carrier Screening for Familial Disease
4.1.1.1 Fragile X
4.1.2 Carrier Screening for Common and Ethnic Genetic Diseases
4.1.2.1 Cystic Fibrosis
4.1.2.2 Spinal Muscular Atrophy
4.1.2.3 Hemoglobinopathies
4.1.2.4 Ashkenazi Jewish Carrier Screening
4.1.3 Other Ethnicities
4.2 American College of Obstetricians and Gynecologists (ACOG)
4.3 American College of Medical Genetics and Genomics (ACMG)
4.4 U.S. Food and Drug Administration (FDA)

5 Global Carrier Screening Market (by Product Type)
5.1 Laboratory Developed Tests (LDT)
5.2 Kits and Assays

6 Global Carrier Screening Market (by Disease)
6.1 Down Syndrome
6.2 Sickle Cell Anemia
6.3 Cystic Fibrosis
6.4 Hemophilia
6.5 Spinal Muscular Atrophy
6.6 Fragile X Syndrome
6.7 Thalassemia
6.8 Other Autosomal Recessive Genetic Disorders

7 Global Carrier Screening Market (by Region)
7.1 North America
7.1.1 North America: Market Dynamics
7.1.2 North America Carrier Screening Market (by Country)
7.1.2.1 U.S.
7.1.2.2 Canada
7.2 Europe
7.2.1 Europe: Market Dynamics
7.2.2 Europe Carrier Screening Market (by Country)
7.2.2.1 Germany
7.2.2.2 U.K.
7.2.2.3 France
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 The Netherlands
7.2.2.7 Belgium
7.2.2.8 Switzerland
7.2.2.9 Denmark
7.2.2.10 Rest-of-Europe
7.3 Asia-Pacific
7.3.1 Asia-Pacific: Market Dynamics
7.3.2 Asia-Pacific, by Country
7.3.2.1 China
7.3.2.2 Japan
7.3.2.3 Australia
7.3.2.4 India
7.3.2.5 South Korea
7.3.2.6 Singapore
7.3.2.7 Rest-of-the-Asia-Pacific
7.4 Latin America
7.4.1 Latin America: Market Dynamics
7.4.2 Latin America, by Country
7.4.2.1 Brazil
7.4.2.2 Mexico
7.4.2.3 Rest-of-Latin America
7.5 Rest-of-the-World

8 Company Profiles

  • 23andMe Inc.
  • BGI
  • CENTOGENE AG
  • Eurofins Scientific
  • Gene By Gene
  • GenMark Diagnostics Inc.
  • Illumina Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Myriad Genetics Inc.
  • Natera Inc.
  • Pathway Genomics Corporation
  • Quest Diagnostics Incorporated
  • Sema4
  • Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/dd1bc8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    

Primary Logo

Powered by EIN News
Distribution channels: Culture, Society & Lifestyle, Science


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release